CensorNet has raised GBP2m in Series A funding. The funds will be primarily invested into bolstering its R&D for its popular platform, which helps organisations manage the risk of cloud applications in an increasingly mobile work environment.
The round was led by Talis Capital, with existing investors and management participating. Vasile Foca has joined the board as investor director.
SMEs and non-profit organisations use CensorNet to visualise, control and protect all internet activity and the use of cloud applications across all devices. CensorNet solutions give greater visibility to senior management and control to IT departments, allowing organisations to address productivity, security and audit issues associated with the growing use of cloud applications and mobile devices.
“The entire CensorNet team are pleased to be working with Talis Capital and we welcome Vasile to the board. We are confident their experience in SaaS and cyber security will prove invaluable as we continue to grow an exciting business,” says CEO Ed Macnair.
CensorNet is active globally across multiple industries. Having recently announced distribution partnerships with Blue Solutions and Caretower, CensorNet also provides white-labelled solutions for MSPs, allowing them to add margin generating robust web and email security services to their portfolio.
“CensorNet has developed a market-leading product suite which caters to the needs of SMEs struggling to respond to the ever more sophisticated cyber security threats. Their experienced team have a track record of building successful software businesses, so we are delighted to be working with them through the next stage of the company’s development,” explains Vasile Foca, co-founder and Director of Talis Capital.
“SMEs generally remain underserved in terms of affordable, high quality cyber security products. CensorNet is well placed to make a significant impact in this market and we are excited to support this growth financing,” adds Matus Maar (pictured), co-founder and Director of Talis Capital.